JP Morgan Keeps Faith in UnitedHealth (UNH) Amid Regulatory Reviews

Despite recent allegations and the expansion of CMS risk adjustment audits for Medicare Advantage plans, JP Morgan analyst Lisa Gill reiterated a Buy rating on UnitedHealth Group (UNH) with a price target of $405. Gill acknowledges potential exposure for large-cap insurers like UNH, Humana, and CVS Health due to the expanded audits, but advises investors to await UnitedHealth’s response and not to factor in any earnings impact at this early stage of the process. The analyst remains confident in UnitedHealth Group stock despite these headwinds.

Analysis

JP Morgan analyst Lisa Gill reiterated an optimistic stance on UnitedHealth Group Inc. (UNH) on May 22, maintaining a Buy rating and a $405 price target, despite recent challenges including unspecified allegations and a new regulatory development. This development involves the Centers for Medicare and Medicaid Services (CMS) announcing an expansion of its risk adjustment data validation (RADV) audits for Medicare Advantage plans on May 21. The analyst acknowledges that quantifying the financial impact of these expanded audits is difficult at this nascent stage. However, it is noted that large-cap insurers such as UnitedHealth Group, Humana Inc., and CVS Health Corp. face significant exposure within the managed care segment due to these audits. Despite these headwinds, and an overall mixed market sentiment signal (0.0) but an optimistic tone from the analyst regarding UNH (ticker sentiment 0.5), the assessment remains confident in UNH's stock. The guidance suggests investors should await UnitedHealth’s official response to the CMS audit developments, as the process is in its early stages, and cautions against prematurely factoring any impact into company earnings projections. The article also briefly notes a preference for certain AI stocks for higher returns, though the primary focus of the analyst's commentary remains on UNH.

Key Decisions for Investors

• Investors may consider maintaining exposure to UnitedHealth Group, supported by JP Morgan's reiterated Buy rating and $405 price target, while closely monitoring the developments related to the expanded CMS RADV audits.
• It is advisable to await UnitedHealth Group's official communications and further details regarding the potential financial implications of the CMS audits before making significant portfolio adjustments, given the current uncertainty and early stage of the process.
• Given the noted exposure of other large-cap insurers like Humana and CVS Health, investors should monitor sector-wide responses and disclosures concerning the RADV audits, as this could indicate broader financial or operational impacts within the managed care industry.